ReviewReviews in urology2013
Prostate-specific antigen: any successor in sight?
Review in Reviews in urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03397030 (Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The diagnostic value of miRNA-141 in prostate cancer: A systematic review and PRISMA-compliant meta-analysis.Medicine · 2020Pooled it
- Pooled it
- A novel platform using homobifunctional hydrazide for enrichment and isolation of urinary circulating RNAs.Bioengineering & translational medicine · 2023Article
- Characterization of proteins, mRNAs, and miRNAs of circulating extracellular vesicles from prostate cancer patients compared to healthy subjects.Frontiers in oncology · 2022Article
- A randomized controlled trial of a home-based exercise program on prognostic biomarkers in men with prostate cancer: A study protocol.Contemporary clinical trials communications · 2020Article
- Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.BMC medical genetics · 2020Article
- Article
- Porphyrins are increased in the faeces of patients with prostate cancer: a case-control study.BMC cancer · 2018Article
- Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer.Colombia medica (Cali, Colombia) · 2018Article
- Evaluation on the diagnostic and prognostic values of long non-coding RNA BLACAT1 in common types of human cancer.Molecular cancer · 2017Article
- Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers.Journal of Cancer · 2016Article
- Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1.Molecular and cellular biochemistry · 2016Article
- Awareness, Interest, and Preferences of Primary Care Providers in Using Point-of-Care Cancer Screening Technology.PloS one · 2016Article
- Prostatic diseases under focus in a university hospital in Eastern Saudi Arabia. A 15-year experience.Saudi medical journal · 2015Article
- Prognostic role of genetic biomarkers in clinical progression of prostate cancer.Experimental & molecular medicine · 2015Article
- IgE immunotherapy against cancer.Current topics in microbiology and immunology · 2015Review
- Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.Prostate international · 2014Article
- KCTD11 tumor suppressor gene expression is reduced in prostate adenocarcinoma.BioMed research international · 2014Article
- Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.Journal of immunology research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is the most frequently diagnosed malignancy and the second leading cause of cancer death in men in the United States and other parts of the world. The lifetime risk of being diagnosed with PCa is approximately 16%. At present, the only widely accepted screening tools for PCa are prostate-specific antigen (PSA) and digital rectal examination. PSA is known to be prostate specific, but not PCa specific, and hence lacks the sensitivity to detect a large number of tumors, especially during the early stages. The PSA level is also known to be affected by many factors, such as medication, inflammation (benign prostatic hyperplasia and prostatitis), and urologic manipulation; hence, the controversy regarding the appropriate level of serum PSA that should trigger a biopsy or have clinical relevance to prostate metastases. Attempts to determine the level of prostate cells in peripheral blood by reverse transcriptase polymerase chain reaction did not significantly improve cancer diagnosis or predict postoperative failure. Therefore, the search continues for a novel biomarker or a panel of markers as well as other possible interventions to improve the use of PSA. This article reviews several possibilities.
Indexed as
Identifiers
24223021PMC3821988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.